Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Banerjee

Showing results (271-280 of 280) with videos related to

Pageof 28
Sort By:
You have reached the last page of results.This site can display upto 280 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 11, 2025
Efficacy and Safety of Avutometinib ± Defactinib in Recurrent Low-Grade Serous Ovarian Cancer: Primary Analysis of ENGOT-OV60/GOG-3052/RAMP 201Susana N Banerjee, Els Van Nieuwenhuysen, Carol Aghajanian, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 13, 2025
Erratum: Efficacy and Safety of Avutometinib ± Defactinib in Recurrent Low-Grade Serous Ovarian Cancer: Primary Analysis of ENGOT-OV60/GOG-3052/RAMP 201Susana N Banerjee, Els Van Nieuwenhuysen, Carol Aghajanian, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 28, 2021
Reduced-Dose Radiation Therapy for HPV-Associated Oropharyngeal Carcinoma (NRG Oncology HN002)Sue S Yom, Pedro Torres-Saavedra, Jimmy J Caudell, et al.
Molecular and Cellular Biochemistry|September 16, 2017
Unprecedented anticancer activities of organorhenium sulfonato and carboxylato complexes against hormone-dependent MCF-7 and hormone-independent triple-negative MDA-MB-231 breast cancer cellsPaul T Wilder, David J Weber, Angela Winstead, et al.
Circulation Research|September 20, 2017
Dose Comparison Study of Allogeneic Mesenchymal Stem Cells in Patients With Ischemic Cardiomyopathy (The TRIDENT Study)Victoria Florea, Angela C Rieger, Darcy L DiFede, et al.
Medrxiv : the Preprint Server for Health Sciences|February 23, 2021
Genome-wide analysis in 756,646 individuals provides first genetic evidence that <i>ACE2</i> expression influences COVID-19 risk and yields genetic risk scores predictive of severe diseaseJ E Horowitz, J A Kosmicki, A Damask, et al.
Medrxiv : the Preprint Server for Health Sciences|March 3, 2021
A catalog of associations between rare coding variants and COVID-19 outcomesJ A Kosmicki, J E Horowitz, N Banerjee, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 20, 2020
Development and Validation of the Gene Expression Predictor of High-grade Serous Ovarian Carcinoma Molecular SubTYPE (PrOTYPE)Aline Talhouk, Joshy George, Chen Wang, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 31, 2020
Prognostic gene expression signature for high-grade serous ovarian cancerJ Millstein, T Budden, E L Goode, et al.
Nature Genetics|March 28, 2017
Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancerCatherine M Phelan, Karoline B Kuchenbaecker, Jonathan P Tyrer, et al.
Pageof 28

Showing results (271-280 of 280) with videos related to

Sort By:
Pageof 28
You have reached the last page of results.This site can display upto 280 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 11, 2025
Efficacy and Safety of Avutometinib ± Defactinib in Recurrent Low-Grade Serous Ovarian Cancer: Primary Analysis of ENGOT-OV60/GOG-3052/RAMP 201Susana N Banerjee, Els Van Nieuwenhuysen, Carol Aghajanian, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 13, 2025
Erratum: Efficacy and Safety of Avutometinib ± Defactinib in Recurrent Low-Grade Serous Ovarian Cancer: Primary Analysis of ENGOT-OV60/GOG-3052/RAMP 201Susana N Banerjee, Els Van Nieuwenhuysen, Carol Aghajanian, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 28, 2021
Reduced-Dose Radiation Therapy for HPV-Associated Oropharyngeal Carcinoma (NRG Oncology HN002)Sue S Yom, Pedro Torres-Saavedra, Jimmy J Caudell, et al.
Molecular and Cellular Biochemistry|September 16, 2017
Unprecedented anticancer activities of organorhenium sulfonato and carboxylato complexes against hormone-dependent MCF-7 and hormone-independent triple-negative MDA-MB-231 breast cancer cellsPaul T Wilder, David J Weber, Angela Winstead, et al.
Circulation Research|September 20, 2017
Dose Comparison Study of Allogeneic Mesenchymal Stem Cells in Patients With Ischemic Cardiomyopathy (The TRIDENT Study)Victoria Florea, Angela C Rieger, Darcy L DiFede, et al.
Medrxiv : the Preprint Server for Health Sciences|February 23, 2021
Genome-wide analysis in 756,646 individuals provides first genetic evidence that <i>ACE2</i> expression influences COVID-19 risk and yields genetic risk scores predictive of severe diseaseJ E Horowitz, J A Kosmicki, A Damask, et al.
Medrxiv : the Preprint Server for Health Sciences|March 3, 2021
A catalog of associations between rare coding variants and COVID-19 outcomesJ A Kosmicki, J E Horowitz, N Banerjee, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 20, 2020
Development and Validation of the Gene Expression Predictor of High-grade Serous Ovarian Carcinoma Molecular SubTYPE (PrOTYPE)Aline Talhouk, Joshy George, Chen Wang, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 31, 2020
Prognostic gene expression signature for high-grade serous ovarian cancerJ Millstein, T Budden, E L Goode, et al.
Nature Genetics|March 28, 2017
Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancerCatherine M Phelan, Karoline B Kuchenbaecker, Jonathan P Tyrer, et al.
Pageof 28